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Summary CYFRA 21-1 assay, measuring cytokeratin 19 fragments, was compared with carcinoembryonic antigen (CEA) assay, as an
addition to cytological analysis for the diagnosis of malignant effusions. Both markers were determined with commercial enzyme
immunoassays in pleural fluid from 196 patients. Cytological analysis and/or pleural biopsy confirmed the malignant origin of the effusion in
99 patients (76 carcinomas, nine pleural mesotheliomas and 14 non-epithelial malignancies). Effusions were confirmed as benign in 97
patients (33 cardiac failures, 39 infectious diseases - including 12 tuberculosis - and 25 miscellaneous effusions). Both markers were
significantly higher in malignant than in benign effusions. All the patients with non-epithelial malignancies presented CYFRA and CEA values
lower than the 95% diagnostic specificity thresholds (100 and 6 ng ml-' respectively). The diagnostic sensitivity in the group of carcinomas
and mesotheliomas was similar for CYFRA (58.8%) and CEA (64.7%). However, CEA had a significantly higher sensitivity in carcinomas
(72.4% vs 55.3%), while CYFRA had a clearly higher sensitivity in mesotheliomas (89.9% vs 0%). Interestingly, 12 out of the 16 malignant
effusions with a negative cytology were CEA and/or CYFRA positive. Regarding their high diagnostic sensitivity and their complementarity,
CEA and CYFRA appear to be very useful for the diagnosis of malignant pleural effusions when cytology is negative.
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The aetiological diagnosis of pleural effusions remains an impor-
tant clinical problem. Cytological analysis detects neoplastic cells
in about 60% ofthe effusions occurring in the course ofmalignan-
cies (Johnston, 1985; Serre et al, 1990). When the cells present in
an effusion cannot be identified as malignant from morphological
and cytochemical criteria only, immunocytochemical labelling
with monoclonal antibodies specific forvarious tumour-associated
antigens often allows their identification and thus slightly
increases the diagnostic sensitivity of cytological analysis (Daste
et al, 1991). Intheremaining cases, whencytology does notpermit
a conclusion, blind pleural biopsy or biopsy under thoracoscopy
must be used (Loddenkemper and Boutin, 1993; Harris et al,
1995). Determination of various tumour markers in pleural fluid,
particularly CEA, has been proposed as a less invasive procedure
to improve the biological diagnosis of malignant effusions
(Rapellino et al, 1990; Villena et al, 1996).
CYFRA 21-1, a new tumour marker assay measuring soluble
fragments of cytokeratin 19, has recently been described
(Bodenmuller et al, 1992). Cytokeratin 19 is amajor component of
the cytoskeleton intermediate filaments of simple epithelium cells
and is overexpressed in various carcinomas (Moll et al, 1982). A
series of concordant studies showed that CYFRA is very suitable
for the diagnosis and the follow-up of non-small-cell lung carci-
nomas, particularly squamous cell carcinomas (Pujol et al, 1993;
Stieber et al, 1993; Van der Gaast et al, 1994). High serum values
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ofCYFRA have also been described in other squamous cell carci-
nomas and in various adenocarcinomas. Thus, the serum perfor-
mances ofCYFRA in lung cancer and its broad spectrum led us to
evaluate its usefulness in the diagnosis of pleural malignant effu-
sions in comparison with CEA and cytology.
MATERIALS AND METHODS
Patients
We retrospectively studied 196 pleural effusions collected from
patients of the Department of Pneumology and Internal Medicine
ofPurpan Hospital in Toulouse, France (Table 1). A definite diag-
nosis was available for all the patients. Malignant pleural involve-
ment was ascertained in 99 patients (54.5% men, aged from 25 to
85 years, median 65 years) by the presence of malignant cells in
pleural fluid and/orinpleuralbiopsy (blind needle biopsy orbiopsy
underthoracoscopy). In a control group of97 patients (57.7% men,
aged from 11 to 89 years, median 73 years), benign disease was
diagnosed and confirmed by follow-up and/or efficiency of a
specific treatment. These two groups were representative of the
main causes ofpleurisies (Serre et al, 1990; Villena et al, 1996).
Cytological analysis and tumour marker assay
Pleural fluid was obtained by thoracocentesis, collected in sterile
tubes without anticoagulant and rapidly brought to the laboratory.
After performing a cell count ofthe sample ofpleural fluid with a
haemocytometer, optimal dilution was carried out to obtain 300
nucleated cells per gl and several samples of 0.7 ml were cyto-
centrifuged at 700 r.p.m. for 17 min in a Cytospin 2 (Shandon,
*The first two authors contributed equally to the work.
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Cheshire, UK). Air-dried slides were stained with the
May-Grinwald-Giemsa method, and absolute ethanol-fixed
slides were stained with the Papanicolaou method, for morpholog-
ical examinations. Periodic acid-Schiff and Alcian Blue (pH 2.5)
cytochemical reactions and immunocytochemical analysis were
also performed on the slides to aid the characterization of suspect
and malignant cells (Daste et al, 1991).
Part of the sample was centrifuged and the supernatant was
aliquoted and stored at-80°C until tumour markerassay. CEA and
CYFRA were assayed in duplicate using two commercial enzyme
immunoassays (MEIA CEA, Abbott, France, and Enzymum Test
CYFRA 21-1, Boehringer Mannheim, France). Dilutions were
carried out, if necessary, with the appropriate diluent as recom-
mended by the manufacturer.
RESULTS
Comparison of CEA and CYFRA in benign and
malignant effusions
The distribution of CEA and CYFRA values in benign and malig-
nant effusions is represented in Figure 1. A significant but very
weak correlation was found between the two tumour markers both
in the benign and in the malignant effusions (r = 0.29, P < 0.04 and
r = 0.22, P < 0.03 respectively). For CEA, the median was
1.0 ng ml-' (range 0.2-36.8) in the benign group, while it was
8.5 ng ml-1 (range 0.5-6760) in the malignant effusions. For
CYFRA, the median was 19.5 ng ml-1 (range 0.5-332) in thebenign
group and 101 ng ml-' (range 2-26 600) in the malignant effusions.
The distribution ofthe values ofeach marker appeared significantly
higher in the malignant than in the benign effusions (P < 10-5).
Data analysis
For both tumour markers, pleural thresholds were defined for a
diagnostic specificity of 95%, i.e. 5% of false positives in the
group ofbenign effusions (Stieber et al, 1993; Van der Gaast et al,
1994). The sensitivities, at this level ofspecificity, were calculated
in various groups of malignant effusions and compared using the
X2 test (or Fisher's exact test according to the size of the groups).
Receiver-operating characteristic curves were also constructed for
CEA and CYFRA by calculating sensitivities and specificities for
several cut-off points, and the areas under the curves were
compared (Hanley and McNeil, 1983). Differences between
groups were tested using the Mann-Whitney U-test. Correlations
were sought by calculating Spearman's rank correlation coeffi-
cient. Differences were considered significant for P < 0.05.
Table 1 Sample of patients
Diagnosis Number
Carcinoma (n = 76)
Lung adenocarcinoma 18
Small-cell lung carcinoma 6
Squamous cell lung carcinoma 2
Breast adenocarcinoma 12
Digestive adenocarcinoma 6
Adenocarcinoma of unknown primary site 27
Other carcinomasa 5
Mesothelioma (n = 9)
Non-epithelial malignancies (n= 14)
Lymphoma/leukaemia 12
Sarcoma 2
Benign (n = 97)
Cardiac failure 33
Parapneumonic 20
Tuberculosis 12
Systemic diseasesb 10
Empyema 7
Liver cirrhosis 4
Otherc 11
alncluding ovary (two), kidney (one) adenocarcinoma and head and neck
squamous cell carcinoma (two). bincluding rheumatoid arthritis (four),
systemic lupus erythematosus (three), Gougerot-Sjogren's syndrome (one),
scieroderma (one) and Sharp's syndrome (one). cincluding post-traumatic
(four), pulmonary embolism (three), benign asbestosis (two), sarcoidosis
(one) and nephrotic syndrome (one).
Diagnostic specificity
The thresholds, corresponding to a diagnostic specificity of 95%,
were 6.0 ng ml-' for CEA and 100 ng ml-1 for CYFRA. None of
the false positives for one marker was afalsepositive forthe other.
For CEA, these false positives were encountered in non-tubercu-
lous infectious pleurisies and for CYFRA in two patients with
cardiac failure, one with tuberculosis and two with empyema.
Interestingly, the two highest values among the false positives
were observed in a context of empyema (9.9 and 36.8 ng ml for
CEA, 208 and 332 ng ml-' forCYFRA).
Diagnostic sensitivity
The diagnostic sensitivities ofCEA, CYFRA and cytology on the
whole population of malignant effusions or in various groups of
patients classified by the histological origin of their cancer are
summarized in Table 2.
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Figure 1 Distribution of pleural fluid concentrations of CEA and CYFRA in
the groups of benign effusions (0), non-epithelial malignancies (*),
carcinomas (-) and mesotheliomas (0). The dotted lines correspond to the
respective 95% specificity thresholds
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Table 2 Diagnostic sensitivity (%) of cytology, CEA and CYFRA according
to the histological type of cancer (with a specificity of 100% for cytology and
of 95% for tumour markers)
Neoplasm Number Cytology CEA CYFRA
All 99 83.8 55.6 50.5
Lymphoma or sarcoma 14 78.6 0 0
Carcinoma or mesothelioma 85 84.7 64.7 58.8
Carcinoma 76 89.5 72.4a 55.3a
Adenocarcinoma 66 87.9 71.2 59.1
Small-cell lung carcinoma 6 100 66.7 0
Squamous cell carcinoma 4 100 100 75
Mesothelioma 9 44.4 o* 89.9a
aSignificant difference between CEA and CYFRA sensitivities.
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Figure 2 Receiver operating characteristic curves for CE
considering the group of benign effusions for specificity ai
carcinomas and mesotheliomas for sensitivity
Among the 99 patients with a malignant effusic
tive cytology (sensitivity of83.8%). For the rema
malignancy was confirmed histologically. The
CEA and CYFRA in malignant effusions were
different (55.6% and 50.5% respectively). All I
lymphomas or sarcomas had low values for both
under the 95% specificity thresholds. Consequent
carcinoma and mesothelioma group was conside]
ties of CEA and CYFRA were found to be highei
significantly different (64.7% and 58.8% respec
used receiver-operating characteristic curves
performances of CEA and CYFRA in this grour
similar appearance of the two curves was cc
comparison ofthe areas under the curves, which c
significant differences between CEA and CYFI
the group of carcinomas, CEA was more effecti
(sensitivity of 72.4% vs 55.3%, P = 0.04). Invers
of mesotheliomas, CYFRA was clearly more dis
tivity of 89.9% vs 0%, P = 0.0004). In mesothe
ranged from 17.2 to 10 120 ng ml-' with a media
while, in carcinomas, CYFRA ranged from 6.1 t
with a lower median of 124 ng ml-'. Despite the
groups of patients with small-cell lung carcinon
cell carcinomas, it is noteworthy that both markers appeared to be
frequently elevated in the group of squamous cell carcinomas,
while only CEA was high in small-cell lung carcinomas (Table 2).
Considering the groups of patients with malignant pleural effu-
sions associated with lung and breast carcinomas, no significant
differences were found between CEA and CYFRA sensitivities.
The combination of CEA and CYFRA clearly improved the
diagnosis sensitivity as 73.3% of malignant effusions and 85.5%
of carcinoma effusions were positive with at least one marker. In
effusions with a positive cytology, sensitivity of CEA was 60.2%,
while 49.4% ofthe patients had CYFRA values over the threshold.
More interesting was the observation of 12 elevated CEA and/or
CYFRA values in the 16 cytologically negative malignant effu-
sions (Table 3). The two markers brought additional information
butCYFRA appeared to be more contributive than CEA as a result
ofits performance with mesotheliomas. Finally, the association of
cytology, CEA and CYFRA allowed the best results to be obtained
as only four malignant effusions out of 99 (two lymphomas, one
sarcoma and one carcinoma) remained negative.
DISCUSSION
Several authors have suggested using the pleural fluid assay of
different tumour markers to improve the cytological diagnosis of
malignant pleural effusions. The purpose ofthis study was to eval-
uate the interest ofthe new tumour marker CYFRA 21-1, which is
CYFRA well documented marker, while only few studies have
CEA been published to date concerning pleural effusions (Satoh et al,
1995; Romero et al, 1996; Toumbis et al 1996). In the present
work, we compare the diagnostic performance ofCYFRA to those
0.2 0.0 of cytology and CEA, in 196 patients with a perfectly defined
diagnosis, consisting of a control group of97 benign effusions and
a group of99 malignant effusions.
EA and CYFRA The two markers were weakly correlated, probably because they
belong to different families of tumour markers. CEA is a well-
known oncofetal protein, while CYFRA corresponds to fragments
ofcytokeratin 19, an intermediate filamentprotein mainly expressed
in the cytoskeleton ofnormal simple epithelial (Moll et al, 1982).
in,
83 had apOsi- Our results regarding CEA (55.6% sensitivity) are concordant
ining 16 patients, with previous data that reported sensitivities of around 50-60% in
sensitivities of malignant effusions (Rapellino et al, 1990; Villena et al, 1996).
not significantly The highest sensitivity logically observed in carcinomas,
the patients with while low values found in mesotheliomas, in agreement
markers, clearly with previous studies (Ebert et al, 1990; Mezger et al, 1990).
tly, when only the
red, the sensitivi-
r but always non-
ctively). We also Table 3 Efficiency of CEA and CYFRA in the 16 malignant pleural effusions
to compare the with a negative cytology
p (Figure 2). The
Dnfirmed by the
lid not reveal any
RA. However, in
ive than CYFRA
sely, in the group
;criminant (sensi-
-liomas, CYFRA
an of201 ng ml',
to 26 600 ng ml-l
small size of the
nas or squamous
Marker(s) over the pleural thresholda
CEA and/or
Neoplasm Number CEA CYFRA 21-1 CYFRA
Lung 1 1 1 1
Breast 1 0 1 1
Unknown primary 6 4 2 5
Mesothelioma 5 0 5 5
Non-epithelial 3 0 0 0
Total 16 5 9 12
aCEA 6 ng ml-' and CYFRA 100 ng ml.
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Compared with the values usually observed in the serum of
patients with benign diseases, the values of CYFRA in benign
effusions appeared to be very high. Indeed, our 95% specificity
threshold was 100 ng ml-l, while, in serum, the widely accepted
cut-off in patients with benign diseases is situated at around 3-
4 ng ml-' (Pujol et al, 1993; Van der Gaast et al, 1994; Plebani et
al, 1995). These large amounts of CYFRA in pleural fluid most
probably originate from mesothelial cells in which cytokeratin 19
is strongly expressed (Larocca and Rheinwald, 1984). In the same
way, high levels of TPA (tissue polypeptide antigen), a tumour
marker corresponding to cytokeratins 8, 18 and 19, have been
reported in benign pleural effusions (Parazzi et al, 1987;
Tokuyama et al, 1995). High values of CYFRA and a similar
threshold (around 90 ng ml-' at 95% specificity) were also
described in benign effusions (Toumbis et al, 1996), while Satoh
et al (1995) and Romero et al (1996) reported a lower cut-off
(21 ng ml-l and 50 ng ml-l respectively) but with a specificity of
only 71.4% and 82% respectively. However, although high values
were observed in benign effusions, CYFRA was significantly
higher in malignant effusions and we noted a reasonable sensi-
tivity (50% at 95% specificity), very close to that of CEA. In
accordance with the non-expression of CEA and cytokeratins in
lymphoma and sarcoma cells, both markers were clearly under the
thresholds in these groups. Consequently, when we only consid-
ered the group ofcarcinomas andmesotheliomas, the sensitivity of
CEA and CYFRA appeared to be significantly higher (64.7% and
58.8% respectively), reaching the levels of sensitivity previously
described for various tumour markers, such as CEA, CA 72-4 or
CA 15-3 (Ferroni et al, 1990; Rapellino et al, 1990; Villena et al,
1996). Satoh et al (1995) and Toumbis et al (1996) described
similar results for CYFRA, but Satoh reported a higher sensitivity
for CYFRA than forCEA. On the otherhand, Romero et al (1996)
observed a sensitivity ofonly 38% forCYFRA, in a small series of
41 malignant effusions. Thus, ourresults agree with those ofSatoh
et al (1995) and Toumbis et al (1996), and we confirm that
CYFRA is one of the most efficient tumour markers available for
the diagnosis ofmalignant effusions.
Here, we also studied the usefulness of CEA and CYFRA in
comparison with cytological analysis. CEA and CYFRA were
frequently high in patients exhibiting a malignant cytology but the
most striking fact was the demonstration of 12 elevated CEA
and/or CYFRA values out ofthe 16 cytologically negative malig-
nant effusions. In fact, the combination of cytology and/or CEA
and/or CYFRA allowed the diagnosis of 95 out of 99 malignant
effusions. Moreover, among the four false negatives, we found
three non-epithelial malignancies. Thus, with the exception of
empyemas, which are infrequently associated with malignant effu-
sions but in which tumour markers may be falsely increased (and
so must be avoided), these easily performed and non-invasive
assays represent a very sensitive association that may alert and
help cytologists when cytology remains suspect or negative. They
also constitute a good argument for physicians to rapidly perform
new thoracocentesis and/or thoracoscopy.
The good diagnostic efficiency ofthe association CEA/CYFRA
in the group of carcinomas and mesotheliomas is directly depen-
dent on their complementarity. Indeed, CEA is more effective in
carcinomas and notably in small-cell lung carcinomas, while
CYFRA is also sensitive in carcinomas but, above all, very sensi-
tive in mesotheliomas. The high performance ofCYFRA in carci-
nomas was expected because elevated levels ofCYFRA had been
described in the serum of patients with adenocarcinomas of the
lung (Pujol et al, 1993; Stieber et al, 1993; Van der Gaast et al,
1994; Plebani et al, 1995), stomach (Nakata et al, 1996), ovary
(Inaba et al, 1996), bladder (Senga et al, 1996) and breast (Molina
et al, 1994). Moreover, CYFRA is presented as the most sensitive
serum tumour marker in squamous cell lung carcinomas (Pujol et
al, 1993; Stieber et al, 1993; Van der Gaast et al, 1994; Plebani et
al, 1995) and is of potential interest in squamous cell carcinomas
of the uterine cervix (Ferdeghini et al, 1994) or head and neck
(Doweck et al, 1995). In pleural effusions, Toumbis et al (1996)
and Satoh et al (1995) observed a high sensitivity for CYFRA in
squamous cell lung carcinomas. Despite the small size of the
group of squamous cell carcinomas, our results lead to the same
conclusion.
On the other hand, this study is the first to describe the great
sensitivity of pleural CYFRA in mesothelioma diagnosis. This
agrees with the expression ofcytokeratin 19 in mesothelioma cells
(Larocca and Rheinwald, 1984) and with the high TPA values in
the pleural fluid of patients with mesothelioma (Parazzi et al,
1987; Tokuyama et al, 1995). Pleural mesotheliomas are malig-
nancies ofincreasing frequency (Peto et al, 1995), and their cyto-
logical and histological diagnosis remains difficult. Although our
results indicate that the diagnosis of mesothelioma must be
suspected when a low CEA is associated with a high CYFRA, this
profile is not specific because some adenocarcinomas have the
same profile. In agreement with Villena et al (1996), who recently
reported high CA 15-3 levels in pleural fluid of seven out of ten
patients with mesothelioma, our preliminary unpublished data
seem to confirm the potential interest of this pleural marker in
mesotheliomas. Hyaluronic acid is also known to have a good
specificity in mesothelioma (Ebert et al, 1990). Hence, low CEA
values associated with high values of CYFRA, CA 15-3 and
hyaluronic acid would strongly suggest a mesothelioma.
In conclusion, our results confimn the high sensitivity of pleural
fluidCYFRA invarious carcinomas andunderscore its greatinterest
in mesotheliomas. We suggest that the association of CEA and
CYFRA is very useful in the diagnosis of malignant effusions,
particularly when cytological analysis does not identify malignant
cells and when the clinical context is compatible with a malignancy.
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